Arthur Kirsch Sells 15,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Arthur Kirsch sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $60.22, for a total value of $903,300.00. Following the sale, the director owned 15,000 shares in the company, valued at $903,300. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Liquidia Stock Performance

LQDA opened at $62.32 on Friday. Liquidia Corporation has a 52-week low of $11.85 and a 52-week high of $66.24. The firm has a market capitalization of $5.54 billion, a PE ratio of 445.20 and a beta of 0.58. The company has a debt-to-equity ratio of 1.18, a quick ratio of 2.03 and a current ratio of 2.22. The business’s 50-day simple moving average is $46.27 and its 200 day simple moving average is $39.40.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The business’s quarterly revenue was up 4187.1% compared to the same quarter last year. As a group, sell-side analysts expect that Liquidia Corporation will post 2.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LQDA has been the topic of several research reports. BTIG Research upped their target price on Liquidia from $50.00 to $59.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research report on Thursday. Needham & Company LLC upped their target price on Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Finally, Oppenheimer upped their target price on Liquidia from $16.00 to $19.00 and gave the company an “underperform” rating in a research report on Thursday, March 12th. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.50.

Institutional Investors Weigh In On Liquidia

A number of large investors have recently added to or reduced their stakes in the stock. Seven Fleet Capital Management LP grew its position in Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after buying an additional 113,609 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Liquidia during the first quarter worth approximately $2,111,000. Bank of America Corp DE grew its position in Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after buying an additional 360,372 shares in the last quarter. California State Teachers Retirement System boosted its holdings in shares of Liquidia by 25.0% in the 1st quarter. California State Teachers Retirement System now owns 72,438 shares of the company’s stock valued at $2,734,000 after purchasing an additional 14,485 shares in the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of Liquidia in the 1st quarter valued at $3,650,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).